{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T10:30:14Z","timestamp":1786962614848,"version":"build-2736575974"},"reference-count":35,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Sciences Foundation of China","doi-asserted-by":"crossref","award":["81570193"],"award-info":[{"award-number":["81570193"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Sciences Foundation of China","doi-asserted-by":"crossref","award":["81770219"],"award-info":[{"award-number":["81770219"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Hematology"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Blinatumomab has gained attention for its effectiveness in improving overall survival in relapsed\/refractory B-cell acute lymphoblastic leukemia (B-ALL) and eradicating minimal residual disease (MRD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>We conducted a retrospective study to assess whether combining reduced-dose blinatumomab with chemotherapy for consolidation could improve outcomes in newly diagnosed B-ALL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Patients with Philadelphia chromosome (Ph)-positive or Ph-negative B-ALL who achieved complete remission (CR) after induction received consolidation therapy consisting of blinatumomab (cycle 1, 3, 5, and 7) and hyper-CVAD (course B for cycles 2 and 6; course A for cycle 4 and 8). After completion of the cycle 2, the decisions to continue treatment or receive hematopoietic stem-cell transplantation were made based on multiple factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The final endpoint was molecular remission, overall survival (OS), relapse-free survival (RFS). Molecular remission referred to MRD-related methods, including MFC (multiparameter flow cytometry)-based MRD, next generation sequencing (NGS)-based MRD, and complete molecular remission (CMR). Meanwhile, we assessed the safety profile of this combination regimen, including adverse events such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>32 newly diagnosed B-ALL patients (14 Ph+ B-ALL and 18 Ph- B-ALL) achieving CR were analyzed. At the time of study inclusion, 12 Ph+ B-ALL and 12 Ph- B-ALL patients were MFC-MRD negative, and 5 Ph+ B-ALL patients achieved CMR. After the first blinatumomab consolidation and hyper-CVAD B cycle, seven additional patients (one Ph+ B-ALL and six Ph- B-ALL) achieved MFC-MRD negativity, and six additional Ph+ B-ALL patients achieved CMR. With a median follow-up of 16.5 months, the overall rate of MFC-MRD was 96.88% (Ph+ B-ALL 92.86% and Ph- B-ALL 100%), and CMR was 78.57%. The estimated RFS and OS rates at 30 months for whole patients were 83.5% (95% CI, 79.1%\u2013100%) and 96.8% (95% CI, 90.8%\u2013100%), respectively. The most common adverse events were observed during chemotherapy cycles due to myelosuppression. Eight patients developed a grade 1-2 blinatumomab-related CRS with a prevalence of 17.78%, which was completely reversible.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Reduced-dose blinatumomab combined with hyper-CVAD chemotherapy as consolidation therapy seems to be feasible for adult B-ALL with acceptable side effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20406207261479931","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T21:29:01Z","timestamp":1786742941000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["The combination of alternating reduced-dose blinatumomab and hyper-CVAD as consolidation therapy in patients with newly-diagnosed adult B-cell acute lymphoblastic leukemia"],"prefix":"10.1177","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-0704-0403","authenticated-orcid":false,"given":"Zixuan","family":"Li","sequence":"first","affiliation":[{"name":"Huazhong University of Science and Technology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Liu","sequence":"additional","affiliation":[{"name":"Huazhong University of Science and Technology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Huazhong University of Science and Technology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9528-4849","authenticated-orcid":false,"given":"Jing","family":"He","sequence":"additional","affiliation":[{"name":"Huazhong University of Science and Technology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"WeiMing","family":"Li","sequence":"additional","affiliation":[{"name":"Huazhong University of Science and Technology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dairong","family":"Xie","sequence":"additional","affiliation":[{"name":"Huazhong University of Science and Technology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Jiang","sequence":"additional","affiliation":[{"name":"Huazhong University of Science and Technology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruofeng","family":"Jin","sequence":"additional","affiliation":[{"name":"Huazhong University of Science and Technology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianran","family":"Gao","sequence":"additional","affiliation":[{"name":"Huazhong University of Science and Technology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3987-1206","authenticated-orcid":false,"given":"Mei","family":"Hong","sequence":"additional","affiliation":[{"name":"Huazhong University of Science and Technology"},{"name":"Soochow University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6488-5731","authenticated-orcid":false,"given":"Qiuling","family":"Wu","sequence":"additional","affiliation":[{"name":"Huazhong University of Science and Technology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"e_1_3_7_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)33018-1"},{"key":"e_1_3_7_3_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.014274"},{"key":"e_1_3_7_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-07-2708"},{"key":"e_1_3_7_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-020-0712-8"},{"key":"e_1_3_7_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.0580"},{"key":"e_1_3_7_7_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00905-2"},{"key":"e_1_3_7_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2024000531"},{"key":"e_1_3_7_9_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10122544"},{"key":"e_1_3_7_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609783"},{"key":"e_1_3_7_11_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-015-0195-4"},{"key":"e_1_3_7_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-798322"},{"key":"e_1_3_7_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008213"},{"key":"e_1_3_7_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26634"},{"key":"e_1_3_7_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.7270"},{"key":"e_1_3_7_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00073-X"},{"key":"e_1_3_7_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312948"},{"key":"e_1_3_7_18_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01597-8"},{"key":"e_1_3_7_19_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2025.7050"},{"key":"e_1_3_7_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"e_1_3_7_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00285-X"},{"key":"e_1_3_7_22_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018019034"},{"key":"e_1_3_7_23_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1780583"},{"key":"e_1_3_7_24_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023012139"},{"key":"e_1_3_7_25_2","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2024000532"},{"key":"e_1_3_7_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00272"},{"key":"e_1_3_7_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2016272"},{"key":"e_1_3_7_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.10.024"},{"key":"e_1_3_7_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70161"},{"key":"e_1_3_7_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7062"},{"key":"e_1_3_7_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33967"},{"key":"e_1_3_7_32_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017035"},{"key":"e_1_3_7_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-025-06351-9"},{"key":"e_1_3_7_34_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-022-01032-5"},{"key":"e_1_3_7_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26622"},{"key":"e_1_3_7_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-022-01220-4"}],"container-title":["Therapeutic Advances in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207261479931","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20406207261479931","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207261479931","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T10:18:22Z","timestamp":1786961902000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20406207261479931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":35,"alternative-id":["10.1177\/20406207261479931"],"URL":"https:\/\/doi.org\/10.1177\/20406207261479931","relation":{},"ISSN":["2040-6207","2040-6215"],"issn-type":[{"value":"2040-6207","type":"print"},{"value":"2040-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"article-number":"20406207261479931"}}